Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2014

View Archived Issues

Discovery of a bacterial class III lanthipeptide with antinociceptive properties

Fidarestat shows potential as an oral therapy for DME

PSMA MAb [177Lu]J-591 tested for treatment of metastatic solid tumors

TRK-170 attenuates chronic colitis in animal model

Epizyme begins pediatric proof-of-concept study of EPZ-5676

Pfizer reviews pipeline activities of first quarter 2014

AV Therapeutics to collaborate with consortium on phase I trials of capridine-beta

Cellmid selects lead anti-MK antibody in oncology

Hisamitsu Pharmaceutical reports data from phase II study of HP-3060

RaQualia enters into trial collaboration for RQ-00000010

Horizon Discovery licenses CRISPR/Cas9 gene editing technology from ERS Genomics

Novira Therapeutics begins phase Ia study of NVR-1221

Anti-miR-145 shows beneficial cardiac effect in models of pulmonary arterial hypertension

Results from phase I trial of XSpray's HyNap formulation of nilotinib

Synta reports results from final analysis of the GALAXY-1 trial

TG Therapeutics provides update on modified TGR-1202 formulation

Idera partners with Abbott on development of companion diagnostic for IMO-8400

Lundbeck to acquire Chelsea Therapeutics, including Northera

Lundbeck advances pipeline in first quarter 2014

NeoStem acquires California Stem Cell

DAV-132 could prevent the side effects of antibiotics on gut flora

FDA grants fast track status to Prima BioMed's CVac program

Amgen patents novel anti-IL-21R antibodies

Shanghai Institute Materia Medica discloses novel HSP90 inhibitors

MedImmune reports development of Abeta-binding antibodies

Novel aminoethyl nitrate compound shows safety and promising vasodilative activity in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...